Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for many malignant hematologic diseases, with an often critical graft-versus-leukemia (GVL) effect. Despite peri-transplant prophylaxis, graft- Given the effectiveness of tolDC in experimental models of GVHD and their safety in early human studies for type 1 diabetes, it is crucial that tolDC be investigated in the prevention and treatment of human GVHD, while ensuring conservation of GVL effects.
Introduction
Hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for many high-risk malignant hematologic diseases, as well as numerous life-threatening genetic and hematological disorders.
However, despite peri-transplant prophylaxis, HSCT is frequently complicated by graft-versus-host disease (GVHD), which leads to significant morbidity and mortality. The risk of GVHD limits the broader application of HSCT where it has the potential to cure autoimmune diseases, facilitate transplant tolerance, and correct immunological deficiencies, including HIV infection. 1 Conventional immunosuppressants remain the mainstay of treatment for GVHD, yet they frequently fail and carry a significant risk for infection. 2, 3 It is therefore of significant interest to identify new, effective and safe prophylactic and therapeutic approaches, particularly those that maintain the critical graft-versus-leukemia (GVL) effect of HSCT. In this review, we consider advances that have been made in understanding the role of dendritic cells (DC) in GVHD and address the challenge of monitoring, targeting and exploiting these cells to improve therapeutic outcomes.
Our understanding of the pathogenesis of GVHD has advanced significantly over the past forty-five years, since
Billingham proposed that GVHD is due to immunocompetent donor cells recognizing recipient antigens (Ags) in an immunocompromised host unable to reject donor cells. 4 The principal immunocompetent donor effector cells are T cells, and the vigor of the immune response is driven by differences in major histocompatibility complex (MHC) and minor histocompatibility antigens (miHA). Furthermore, the crucial role of Ag-presenting cells (APC), in particular uniquely well-equipped donor and recipient DC, has begun to be elucidated, not only in GVHD, but also in the GVL effect of HSCT.
DC hematopoiesis and immunobiology
DC are rare, heterogenous bone marrow (BM)-derived professional APC, first characterized in mouse spleen by
Steinman & Cohn, 5 that are distributed ubiquitously in blood, lymphoid and peripheral tissues, especially at portals of entry. They arise from hematopoietic stem cells through specialized progenitor subsets 6 and are important in innate and adaptive immune function and in determining the balance between immunity and
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From tolerance. In the normal steady-state, DC reside in 'immature' or 'semi-mature' states in the periphery where they constantly take up and process self-Ags and maintain self-tolerance. 7 Immunostimulatory DC have undergone maturation following recognition of exogenous and endogenous alarmins/danger signals by Toll-like receptors (TLR). 8 These signals include pathogen-associated molecular patterns (PAMPS) in the form of microbial products and danger-associated molecular patterns (DAMPS), such as products of damaged or dying cells (e.g. high-mobility group protein B1 or DNA). DC are also matured by CD40 ligation and by proinflammatory cytokines that can induce DC maturation ex vivo, independent of CD40 ligation. Maturation is associated with upregulation of cell surface MHC gene products, co-stimulatory molecules (CD40, CD80 and CD86, in addition to CD83 in humans) and appropriate chemokine receptors (in particular CCR7) that enhance the ability of DC to home to secondary lymphoid tissue. Therein they present Ag to Ag-specific T cells and induce T cell activation/proliferation. In turn, activated T cells drive DC towards terminal maturation. These aspects of DC immunobiology have been reviewed in detail. [9] [10] [11] [12] DC develop from HSC in the BM and are derived from both myeloid and lymphoid progenitors (FIGURE 1). [13] [14] [15] [16] This has been demonstrated in both mouse and human studies, in which all DC subsets can be generated from either a common lymphoid progenitor (CLP) or common myeloid progenitor (CMP). 6, [17] [18] [19] The hematopoietic growth factor fms-like tyrosine kinase 3 ligand (Flt3L) plays a central role in steady-state DC development; this is evidenced by the majority of DC precursors being Flt3 + (CD135 + ) and culture with Flt3L resulting in all major DC subsets. 6, 17, 20, 21 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also important in DC hematopoiesis, as it gives rise to DC from monocytes and early progenitors in the absence of intact Flt3L signaling and produces DC under inflammatory conditions. 6, 17 Monocyte/macrophage (M)-CSF is also a DC poietin and can drive DC generation in mice independently of Flt3L.
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DC Subsets (i) Overview of subsets
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From DC can be broadly categorized as conventional DC (cDC) and precursor DC (FIGURE 1). 17 In the steady-state, cDC exhibit typical DC features (e.g. cytoplasmic dendrites) and function (e.g. Ag uptake, processing, and presentation). 17 cDC can be subdivided into migratory DC, such as skin epidermal Langerhans cells (LC) and dermal DC, that present Ag in lymph nodes following its uptake in peripheral tissue, and resident DC that take up and present Ag within a lymphoid organ, such as splenic or thymic DC (TABLE 1) . 6, 17 Resident DC can be further categorized in the mouse as CD8α -, which is the predominant splenic population, and CD8α + , which is the major thymic population. 6, 17 CD8α + DC are involved in Ag cross-presentation and show high IL-12 secretion. 6, 17 Thymic cDC primarily present self-Ag and are important in self-tolerance through T cell negative selection and the production of naturally-occurring regulatory T cells (T reg ). [23] [24] [25] Plasmacytoid DC (pDC) are a subset of precursor DC which have an immature phenotype in the steady-state and plasma cell morphology (e.g. lack dendrites). 17 Upon activation, pDC closely resemble cDC in form and function. 17 Monocyte-derived DC or 'inflammatory DC' are similar to cDC in form and function and correlate with in vitro GM-CSF generated DC.
17
(ii) Function of DC subsets DC subsets differ in their immune functions, which has important implications for HSCT. Under steady-state conditions, human pDC display lower levels of MHC and co-stimulatory molecules compared to conventional myeloid (m)DC. 26 Also, since their Ag processing and loading ability is less efficient, pDC stimulate T cells less effectively than mDC. 26 Following their activation via TLR, pDC secrete high levels of type-1 interferon (IFN) and stimulate CD4 + and CD8 + T cells. 11 This is in contrast to activated mDC, which secrete IL-12 and promote T-helper type-1 (Th1) cell differentiation and CD8 + CTL responses. 26, 27 pDC have intrinsic tolerogenic properties; in the steady-state, human thymic pDC induce T reg , while liver and airway pDC regulate oral and mucosal tolerance, respectively. pDC have also been implicated in the regulation of disease activity in experimental models of autoimmunity and shown to exert disease-suppressing ability. 28 This may be important following HSCT in terms of donor BM engraftment (tolerance), as well as for chronic GVHD (cGVHD) which 
DC tolerogenicity
In addition to their capacity to stimulate innate and adaptive immunity, DC can induce and maintain tolerance (for reviews, see 28, 39, 40 ). Tolerogenic (tol) DC present Ag to T cells, but lack adequate co-stimulatory ability, deliver inhibitory signals (e.g. via the programmed death [PD] pathway), and produce tolerance-promoting cytokines (IL-10). 39 TolDC do not support Ag-specific T cell activation and proliferation, but instead facilitate T cell anergy/apoptosis and/or the generation or expansion of T reg . 39 Importantly, bidirectional feedback between tolDC and T reg has been demonstrated in humans and mice, whereby tolDC promote the generation of T reg from naïve T cells and T reg generate tolDC from DC progenitors. 41 Regulation of immunosuppressive tryptophan catabolism in DC via activation of indoleamine 2,3-dioxygenase (IDO) may be an important mechanism of action of Treg 42 and may underlie transplant tolerance in vivo. The close relationship between T reg and DC is illustrated by the observation that increases in DC lead to increases in T reg , whereas constitutive absence of DC leads to fatal autoimmunity.
43-45
Role of DC in the pathogenesis of GVHD
Mouse studies have demonstrated that CD4 + T cell-dependent (MHC-mismatched) acute GVHD (aGHVD) can be induced by either host or donor APC, whereas host APC are required for the initiation of CD8 + T celldependent (MHC-matched, multiple miHA-mismatched) aGVHD and donor APC amplify the process. [46] [47] [48] Additional studies have tried to further characterize the contribution of different APC populations to the development of aGVHD. While earlier mouse studies implicated host LC in the pathogenesis of skin GVHD, more recent experiments using mice deficient in LC question the relevance of LC in the development of aGVHD.
49,50
For personal use only. 54 This has important implications, both in the pathogenesis of cGVHD, but also in its prevention, as keratinocyte growth factor prevents cGVHD likely due to thymic protection.
54
The development of GVHD, particularly aGVHD, has been divided traditionally into three phases (FIGURE 2).
Phase I involves activation of APC, particularly DC, by cytokines released following recipient tissue damage.
These DC present acquired and processed Ag to T cells, which, in combination with simultaneous costimulation, leads to the second phase,-donor T cell activation. Clinical studies have demonstrated that increased graft pDC content is associated with relapse and decreased patient overall survival. 63 Low CD11c + DC, but not CD123 + DC, in peripheral blood (PB) at the time of engraftment has also been associated with death and relapse. 64 New insights concerning the role of both donor and recipient DC subsets in GVL, including graft precursor pDC content, and the impact of pre-transplant manipulation of these subsets are clearly needed.
The role of DC in GVL following donor leukocyte infusion (DLI) has also been examined. In murine and clinical studies, GVL effects can be seen following DLI without GVHD. 65 The presence of host APC and allo-MHC I has been shown to be critical for GVL effects in mixed chimeras created in the fully MHC-mismatched setting, although results are not as clear in the MHC-matched minor Ag mismatched and clinical settings.
66-68
Furthermore, there is evidence that DLI-induced GVL effects in mice are dependent on MHC alloAg, but not miHC or tumor-associated Ags, in a CD4 + and CD8 + T cell-dependent manner, and that MHC class IIexpressing host APCs are required for maximal GVL activity. 60 Unfortunately, while DLI enhances the GVL effect, it is often complicated by GVHD.
69,70
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Influence of transplant factors on DC in relation to GVHD
Given the role of host tissue damage in the pathogenesis of GVHD, it was thought that reduced intensity conditioning (RIC) would lead to less GVHD. However, while RIC has reduced transplant-related mortality, the incidence of aGVHD, while delayed, remains unchanged. In mouse HSCT following RIC, Turner et al 71 demonstrated that, while the onset of GVHD was delayed, it was equally severe. The authors hypothesized that delays in GVHD were due to maintenance of absolute numbers of host DC and decreased TNFα production, promoting T reg responses. 71 As donor chimerism increased, donor-activated DC increased and elevated TNFα led to decreased T reg and onset of delayed, yet equally severe GVHD. 71 Conditioning regimens can differ in host irradiation, however some human and mouse DC are resistant to radiation, particularly dermal DC and epidermal LC. [72] [73] [74] In an experimental model, total body irradiation (TBI)
led to complete depletion of splenic and BM pDC after 24 hours, whereas mDC were maintained, but in decreased numbers. 75 Additionally, TBI is important in DC activation; studies in mice have shown that inflammation from irradiation is critical for pDC but not mDC activation. 26 HSC may be obtained either directly from BM or from the PB following expansion with granulocyte colonystimulating factor (G-CSF). As reviewed by Korbling et al, 76 despite a significant increase in donor T cells in PB stem cell (PBSC) grafts, there is surprisingly no increase in aGVHD, although there seems to be an increase in cGVHD. 76 Numerous studies have documented increased graft pDC with G-CSF mobilization, with potential implications for outcome of HSCT, including that these cells may favor Treg function. [77] [78] [79] G-CSF treatment has also been associated with decreased pro-inflammatory IL-12 production. In a mouse model of PBSC transplantation, G-CSF treatment of donors rather than recipients significantly reduced levels of TNFα, likely via decreased donor DC TNFα and IL-12 production. 80 mDC IL-12 production was also significantly decreased in pediatric HSCT recipients who received G-CSF post transplantation. 81 These differences must be taken into account when interpreting clinical studies. Table 2 )
DC analyses in relation to outcome of HSCT (summarized in
Clinical studies have revealed an association between low total DC numbers at the time of engraftment and decreased patient overall survival (OS), increased relapse, and increased aGVHD. 64 Neither host DC count pretransplant nor graft DC count was associated with death or relapse. 64 Though neither was independently significant, lower mDC count at engraftment was associated with decreased survival, increased relapse, and increased incidence of aGVHD. 64 Lower circulating pDC count correlated only with increases in aGVHD. 64 Skin GVHD has been associated with decreased human LC engraftment. 49, 82 However, this is thought to be a secondary effect related to steroid treatment and GVHD effector cells, as experimental studies have shown that donor T cells promote donor LC engraftment. 49, 82 Prospective studies are indicated to determine if low DC count at the time of engraftment can be used as a predictive tool for GVHD.
(ii) DC chimerism
There are conflicting data on DC chimerism following HSCT. Early human studies demonstrated an association between full donor chimerism and cGVHD as compared to mixed chimerism in some control patients without cGVHD. 83 Chan et al 84 assessed DC chimerism 100 days post transplant and found that host DC persistence correlated with severe aGVHD and cGVHD. There were significant differences between the two studies, however, with the latter involving primarily RIC regimens and samples differentiated in vitro and analyzed by DNA PCR banding, rather than by conventional flow cytometry. 84 Given the differential effects of MAC versus RIC, further studies on DC chimerism in both populations are warranted to resolve the impact of DC chimerism on development of acute and cGVHD.
(iii) DC activation status
The activation status of DC is likely important in and potentially predictive of GVHD. Lau et al 85 examined
expression of CMRF-44, a cell surface marker which is expressed early during the activation and maturation of human mDC, but not on freshly-isolated DC from healthy controls. The incidence of circulating CMRF-44 + CD11c + DC correlated with onset and severity of aGVHD and was found to be predictive when used as a screening test before the onset of GVHD. 85 In the same study, cell surface expression of CD83 and CD86, both of which are increased upon human DC activation and are important in T cell co-stimulation, were not predictive of GVHD. 85 Larger studies investigating the predictive role of these DC activation/maturation markers and their anti-inflammatory versus pro-inflammatory cytokine production, such as IL-10 or IL-12 respectively, should be performed. Analysis of donor versus host origin DC expression of these immunoregulatory molecules could enhance the insights from these further evaluations.
(iv) DC subsets
Prior to current immunophenotyping of DC subsets, Waller et al 86 demonstrated an association between high BM graft presumptive pDC progenitors and decreased cGVHD, although the incidence of leukemic relapse was increased. A more recent clinical study did not find an association between G-CSF-mobilized PB graft pDC content and GVHD, however it confirmed the increased incidence of relapse, as well as decreased OS and event-free survival. 86 Since these studies utilized different stem cell sources, the difference in the incidence of GVHD may be accounted for, in part, by differences in cytokine release and/or DC activation status following G-CSF administration. 86 The association between relapse and graft pDC highlights the importance of preserving the GVL effect with any intervention to decrease GVHD.
Human DC subsets have also been examined in the post-transplant period. Reddy et al 64 documented a dependent association between low CD11c + DC in PB at the time of engraftment and death, relapse and aGVHD; low CD123 + DC count was associated with aGVHD only. More recent studies in patients following MAC and RIC found a significant correlation between pDC count and increased GVHD, as well as pDC and mDC count and increased GVHD severity. 63, 85, 87 Low pDC count 3 months following RIC transplant was also associated with severe aGVHD, decreased OS, and increased non-relapse mortality, notably from GVHD and late infections. 88 As with other analyses, there have been conflicting reports, as an earlier study associated high pDC count with cGVHD, although this was at a median of 14.5 months post transplant. 83 Larger studies comparing DC subsets following various conditioning regimens may help elucidate the differences between studies.
DC subsets have been examined extensively in experimental GVHD. By adoptively transferring DC into MHC II-deficient recipient mice, both pDC and cDC were found to be sufficient to induce comparable donor CD4 + T cell-dependent GVHD, although pDC required an inflammatory environment created by host irradiation for activation and donor T cell priming. 26 Thus, pDC expressing alloAg were sufficient to prime alloreactive T cells and induce GVHD. Similar to human studies, low pDC (depleted by 120G8 Ab to BM stromal cell Ag-2)
in the BM graft led to increased aGVHD, while there was no association between GVHD and pDC count in G-CSF mobilized grafts. 75 The authors indicated that these latter pDC were mature, which may account for the difference in incidence of GVHD. Additionally, while cDC reconstitution did not differ between control and GVHD mice, pDC maturation was abrogated in GVHD. 75 Interestingly, GVHD led to a suppressive precursor DC population that may contribute to immune paralysis post transplant. 75 These findings concerning the role of DC subsets provide important insight into potential strategies for tolerance induction in HSCT.
Influence of current GVHD therapies on DC
Many current therapies significantly affect DC phenotype and function. 89 More precisely, calcineurin inhibitors (CNI; cyclosporine or tacrolimus) suppress Ag presentation, while glucocorticosteroids inhibit DC maturation, activation and production of TNFα, IL-1β, and IL-12 following stimulation. [90] [91] [92] DC generated in the presence of CNI or rapamycin (sirolimus; the serine-threonine kinase inhibitor of the mammalian target of rapamycin
[mTOR]) have decreased costimulatory molecule expression and T-cell allostimulatory capacity. 90, 93 In addition, epidermal LC exposed to glucocorticosteroids are phenotypically immature and expand T reg via transforming growth factor (TGF)-β production. 94 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From experimental models, while preserving GVL. [103] [104] [105] Clinical testing of HDAC inhibition using agents such as SAHA (vorinostat) in conjunction with CNI for the prophylaxis of GVHD following RIC allogeneic HSCT is in progress. 103, 104 Proteasome inhibitors have been studied in cancer and auto-immunity and are thought to induce apoptosis by blocking the degradation of pro-apoptotic proteins. Bortezomib, approved for the treatment of multiple myeloma, is believed to block the activation and nuclear translocation of nuclear factor (NF)-κB, a transcription factor central to DC maturation and inflammatory responses. Thus, inhibition of DC NF-κB activation with bortezomib or other inhibitors is an attractive strategy GVHD prevention. 106 Immature DC treated with bortezomib fail to upregulate MHC-II and co-stimulatory molecules in response to maturation signals, have decreased T cell allostimulatory capacity, and are more susceptible to apoptosis. 106, 107 In experimental HSCT, bortezomib attenuates aGVHD, yet preserves GVL. 106, 107 While early treatment post-HSCT prevents mild aGVHD in mice, later treatment increases mortality significantly, 108 which may reflect loss of early effects on immature DC. Notably, histopathological observations in later bortezomib treatment have implicated severe colonic damage in increased GVHD-dependent mortality. 106 RelB, an NF-κB family subunit, has been shown to be critical within both host and donor APCs for the induction and maintenance of experimental GVHD. 109 RelB in APC is required for differentiation of Th1 effectors, but not for expansion or function of donor T reg . 109 Inhibition of nuclear RelB translocation, with RelB inhibitors targeted to DC using Ab, thus appears to be an attractive strategy for therapy of GVHD. 109 Although these studies confirm NF-κB in DC as an important therapeutic target, they also urge caution when considering bortezomib for the treatment of established GVHD given that late (versus early) treatment in an experimental model significantly increased mortality.
(
ii) Biologic interventions
There is recent evidence that anti-CD83 (polyclonal Ab) decreases T cell proliferation induced by DC, while maintaining anti-viral T cell memory. 110 In an experimental model, anti-CD83 therapy prevented GVHD, while preserving HSC engraftment and GVL. 110 Co-stimulatory signal blockade also prevented experimental GVHD, with the most significant effect achieved by blocking ICOS (using mAb) and CD28 (CD28 -/-donor T cells) with intact CTLA-4 signaling. 55 Further mechanistic and therapeutic studies of mAbs directed against activated DC are clearly justified.
Generation of tolDC for prevention or treatment of GVHD (summarized in Table 4) DC can be manipulated in vitro to produce tolDC or 'negative DC vaccines' for control of alloimmunity or allograft rejection. TolDC may be produced under specific culture conditions, by pharmacological modification, or by cell sorting. Early studies showed that immature DC generated from BM cells in GM-CSF, and with weak allostimulatory T cell capacity, could prolong organ allograft survival. 111, 112 Subsequent reports have verified and extended these findings to show that immature or maturation-resistant tolDC can promote tolerance in experimental organ and HSCT, 39, 113, 114 while still protecting against leukemia relapse.
114
Pharmacologic manipulation of DC (e.g. using dexamethasone, rapamycin or IL-10) renders DC maturationresistant and enhances their tolerogenic potential for inhibition of allograft rejection and GVHD. As an example, rapamycin-treated DC (RAPA-DC) resist maturation and have impaired capacity to stimulate allogeneic effector T cells, yet promote T reg . 93 When adoptively transferred to organ graft recipients, RAPA-DC promote transplant survival and, in conjunction with a short course of host immunosuppression, can induce indefinite graft survival. 93, 115, 116 When administered systemically in experimental GVHD, host-derived RAPA-DC traffic to secondary lymphoid tissue and improve both survival and histopathological grade of GVHD. 117 Similarly, vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide that has been used to generate host-derived tolDC that increase T reg and abrogate aGVHD, while maintaining GVL. 118 Interestingly, early administration (by day +5) of these tolDC is critical in the MHC-mismatched model. abrogates experimental GVHD mortality. 121 Cell sorting can be used to isolate/purify tolDC. Murine CD8α + DC are the principal DC subset involved in cross-presentation (Table 1) and have tolerogenic properties. 124 In both MHC-and miHA-mismatched models of aGVHD, immunization of recipients with ex vivo-generated and FACS-sorted autologous CD8α + DC pretransplant reduces GVHD in an IL-10-dependent, Ag-specific manner. 124 These results confirm the therapeutic ability of CD8α + DC to modify aGVHD, as shown in earlier studies in which Flt3L administration expanded CD8α + DC in vivo and reduced aGVHD. 125 Ildstadt and colleagues have also described how CD8α 128 Overall, distinct subsets of ex vivo-fashioned tolDC or endogenous DC have potential for therapy of GVHD and an important question is which subset is best-suited for therapeutic application. MSC have shown promise in the prevention and treatment of GVHD. As reviewed by Baron et al, 134 while various mouse models have generated conflicting results, they suggest the importance of MSC dose, timing, and activation status. Phase I-II human studies have demonstrated safety and possible efficacy, and multicenter randomized blinded trials on currently underway. 134 Interestingly, the combination of rapamycin and MSC following experimental cardiac transplantation led to long-term graft survival with significantly increased splenic T reg and tolDC. 135 This also highlights the capacity of synergistic therapies in the promotion of tolerance. 135 For
Myeloid-derived suppressor cells (MDSC)
MDSC are heterogeneous hematopoietic precursor cells with immunosuppressive properties, first noted to aid tumor evasion in mice and humans. 136 As reviewed by Lees et al, 137 MDSC modulate both innate and adaptive immunity. While many of their functions are attributed to direct effects on T cells, MDSC additionally inhibit the differentiation and maturation of DC. In mice, MDSC generated from BM cells in G-CSF, GM-CSF, and IL-13 (MDSC-IL-13) were more potent inhibitors of MHC-mismatched GVHD than conventional MDSC. 136 This inhibition was dependent on the L-arginine depleting enzyme arginase. 136 Importantly, MDSC-IL-13 do not impair the GVL effect in vivo.
(iii) T reg
As a bidirectional tolerogenic feedback loop exists between T reg and tolDC, T reg therapy supports tolerance through effects on DC. 41 DC also control the number and function of T reg . 44 Host APC alloAg expression is necessary and sufficient for T reg function in both miHA-and MHC-mismatched mouse models of GVHD, independent of APC IL-10 or IDO expression. 138 In addition, human T reg (generated via CD127 [IL-7Rα] negative selection) and T reg -conditioned DC can abrogate xenogeneic GVHD via induction of immunosuppressive PD-L1 expression on conditioned DC and on effector T cells in vivo. 56 Furthermore, Agspecific T reg can be induced and expanded by DC, as demonstrated by human monocyte-derived DC in an IDOdependent manner. 139 Adoptive transfer of T reg is highly effective in the prevention of experimental GVHD, thus phase I trials are underway with initial studies demonstrating safety and some efficacy. 140, 141 A major impediment to T reg therapy has been the generation of sufficient cell numbers, particularly for natural T reg (nT reg ). 141 Interestingly, the addition of rapamycin (for restimulation of nT reg or for the generation of iT reg with TGF-β) increases T reg yields, which may allow completion of dose escalation trials.
141
Active clinical trials utilizing interventions that target/impact dendritic cells (summarized in There are numerous open clinical trials for the prevention or treatment of GVHD currently studying pharmacologic or biologic interventions and cellular therapies that target or impact DC (Table 5 ). While not listed in Table 5 , there are also many ongoing trials assessing the impact of conventional GVHD therapies (e.g. corticosteroids, CNI, rapamycin) used in new combinations and via different routes (e.g. topical, intra-hepatic, etc). Cellular therapy remains particularly intriguing, with the majority of active studies utilizing MSC. A single trial has been underway testing autologous DC in the setting of relapsed hematologic malignancy; although the DC are not being used for the prevention or treatment of GVHD, GVHD is a primary outcome measure of the study and the trial will hopefully demonstrate safety and feasibility of DC therapy in the SCT setting.
Conclusions
Despite therapies that broadly target effector T cells or globally suppress immunity, GVHD remains a significant cause of post-HSCT morbidity and mortality. Given the tolerogenic potential of some DC subsets and the critical role of others in the pathogenesis of GVHD, differences in DC characteristics may be used to predict outcome while targeting DC is an innovative treatment approach. Likewise, DC may be targeted directly in vivo through molecular pathways or cell surface expression of maturation markers or costimulatory molecules, or tolDC may be generated in vitro and given in the peri-transplant period (summarized in Figure 4 ).
Other cellular therapies, including T reg , mediate dominant immunosuppressive effects by restraining DC stimulatory functions. Given the importance of the GVL effect, any therapy targeting or utilizing DC must conserve this process.
Further understanding of the precise immunoregulatory properties of DC and the development of DC-based therapies for GVHD will expand HSCT use beyond treatment of malignant disease and allow its use in patients lacking MHC-matched donors. Early work by Shlomchik et al 2, 46 elucidated the critical role of miHA expression by host hematopoietic APC for CD8 + T cell-driven GVHD; thus, therapies that orchestrate the successful and timely suppression and/or ablation of host DC are expected to be particularly beneficial to Finally, given the role of both DC and T cells in the pathogenesis of GVHD, synergistic therapies or those that target both cell types in vivo may be more effective. Cellular therapies, specifically tolDC and T reg , are intriguing in their ability to modulate one another in vivo. Importantly, cellular therapies have begun in humans. Human tolDC have been generated and characterized in vitro using clinical grade reagents. 143 Recently, a DC-based vaccine for the treatment of prostate cancer was approved by the FDA, 144 and the first report has appeared of a phase I safety study of tolDC in patients with type 1 (autoimmune) diabetes. 145 As other forms of innovative cell therapy, including testing of Treg, are underway for the prevention of GVHD, 140, 141 there would appear to be adequate justification for phase I studies of tolDC alone and in combination with T reg in HSCT.
Acknowledgments
This work was supported by National Institutes of Health grants (R01AI67541 and R01AI60994 to AWT, R01HL93716 and RO1GM63569 to MYM, and K99/R00 HL97155 to HRT) and the Pittsburgh Foundation (MYM). We thank Brian Rosborough for critical reading of the manuscript.
Authorship contribution
EOS and AWT wrote the manuscript, HRT assisted in writing the manuscript and generation of the figures, MYM assisted in editing the manuscript. The authors have no conflicts of interest.
For 
